Articles dans des revues avec comité de lecture (34)
  1. 13. Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W. W., Del Rincón, S. S., Awada, A., Ghanem, G. E., & Journé, F. (2021). Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-kit. Molecular cancer research, 19(7), 1221-1233. doi:10.1158/1541-7786.MCR-20-1040
  2. 14. Jeschke, J., Collignon, E., Al Wardi, C., Krayem, M., Bizet, M., Jia, Y., Garaud, S., Wimana, Z., Calonne, E., Hassabi, B., Morandini, R., Deplus, R., Putmans, P., Dube, G., Singh, N. K., Koch, A., Shostak, K., Rizzotto, L., Ross, R. L., Desmedt, C., Bareche, Y., Rothé, F., Lehmann-Che, J., Duterque-Coquillaud, M., Leroy, X., Menschaert, G., Teixeira, L., Guo, M., Limbach, P. A., Close, P., Chariot, A., Leucci, E., Ghanem, G., Yuan, B., Willard-Gallo, K., Sotiriou, C., Marine, J.-C., & Fuks, F. (2021). Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. Nature Cancer, 2(6), 611-628. doi:10.1038/s43018-021-00223-7
  3. 15. Sabbah, M., Najem, A., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2021). Rtk inhibitors in melanoma: From bench to bedside. Cancers (Basel), 13(7), 1685. doi:10.3390/cancers13071685
  4. 16. Cogels, M., Rouas, R., Ghanem, G. E., Martinive, P., Awada, A., Van Gestel, D., & Krayem, M. (2021). Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Frontiers in oncology, 11, 784947. doi:10.3389/fonc.2021.784947
  5. 17. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title. Cancers (Basel), 12(10), 2981, 1-2. doi:10.3390/cancers12102981
  6. 18. Soumoy, L., Wells, M., Najem, A., Krayem, M., Ghanem, G. E., Hambÿe, S., Saussez, S., Blankert, B., & Journé, F. (2020). Toad venom antiproliferative activities on metastatic melanoma: Bio-guided fractionation and screening of the compounds of two different venoms. Biology, 9(8), 218, 1-16. doi:10.3390/biology9080218
  7. 19. Soumoy, L., Schepkens, C., Krayem, M., Najem, A., Tagliatti, V., Ghanem, G. E., Saussez, S., Colet, J.-M., & Journé, F. (2020). Metabolic reprogramming in metastatic melanoma with acquired resistance to targeted therapies: Integrative metabolomic and proteomic analysis. Cancers (Basel), 12(5), 1323. doi:10.3390/cancers12051323
  8. 20. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers (Basel), 12(2). doi:10.3390/cancers12020512
  9. 21. Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journé, F., Awada, A., Ghanem, G. E., & Van Gestel, D. (2019). The benefit of reactivating p53 under MAPK inhibition on the efficacy of radiotherapy in melanoma. Cancers (Basel), 11(8), 1093. doi:10.3390/cancers11081093
  10. 22. Chi, V. L. D., Garaud, S., De Silva, P., Thibaud, V., Stamatopoulos, B., Berehad, M., Gu-Trantien, C., Krayem, M., Duvillier, H., Lodewyckx, J. N., Willard-Gallo, K., Sibille, C., & Bron, D. (2019). Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients. BMC cancer, 19(1), 81. doi:10.1186/s12885-019-5276-2
  11. 23. Krayem, M., Najem, A., Journé, F., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2018). Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 9(61), 31888-31903. doi:10.18632/oncotarget.25879
  12. 24. Djehal, A., Krayem, M., Najem, A., Hammoud, H., Cresteil, T., Nebigil, C. C., Wang, D., Yu, P., Bentouhami, E., Atassi, G., & Désaubry, L. (2018). Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells. European journal of medicinal chemistry, 155, 880-888. doi:10.1016/j.ejmech.2018.06.052
    13. << Précédent 1 2 3 Suivant >>